DRL gets adverse ruling in US over patent infringement case

NEW DELHI: Drug major Dr Reddy's Laboratories today said it has received an unfavourable ruling in a US court regarding a patent infringement case over anti-nausea injection Aloxi.

In a BSE filing, Reddy's Laboratories said: "The United States District Court for the District of New Jersey issued its opinion regarding Helsinn Healthcare's patent infringement claims against Dr Reddy's proposed palonosetron product".

"The court found that Dr Reddy's proposed palonosetron hydrochloride 0.25 mg/5 ml infringes on certain claims of US patents...and that the asserted claims were not valid".

Helsinn Healthcare SA is a Switzerland-based pharma company.

"We are disappointed in the decision and intend to pursue an appeal in due course," a company spokesperson said.

Aloxi injection is used in adults to help prevent the nausea and vomiting due to chemotherapy.

Shares of Dr Reddy's were trading at Rs 2,876.25 apiece, down 1.16 per cent on BSE.